News
First Quarter 2006 Product Candidate Highlights
Advanced Life Sciences is developing cethromycin, a novel once-a-day ketolide antibiotic in response to the emerging antibiotic resistance observed in the treatment of community acquired pneumonia (CAP).
Cethromycin has been tested in approximately 3,800 human subjects during clinical trials.
The company is currently conducting pivotal Phase III clinical trials of cethromycin for the treatment of mild-to-moderate CAP. Advanced Life Sciences believes that cethromycin, if approved, would build upon the growing market acceptance of ketolide drugs in the antibiotic marketplace and address the growing need for antibiotics that overcome bacterial resistance.
In the first quarter, the company completed its PIPE equity offering of common stock and warrants, raising $33.6 million in net proceeds.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The company's lead candidate, cethromycin, is a novel once-a-day ketolide antibiotic in late-stage clinical development for the treatment of respiratory tract infections.